J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering

Teclistamab, a BCMAxCD3 bispecific antibody, has won its first global nod in Europe to treat relapsed and refractory multiple myeloma after at least three prior therapies, J&J said Wednesday. In Europe, the company will sell the med under the brand name Tecvayli.